BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ΕΔΕ - Ελληνική Διαβητολογική Εταιρεία - ECPv6.8.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.ede.gr
X-WR-CALDESC:ΕΔΕ - Ελληνική Διαβητολογική Εταιρεία - Εκδηλώσεις
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Athens
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190308
DTEND;VALUE=DATE:20190310
DTSTAMP:20261023T215822
CREATED:20181204T140606Z
LAST-MODIFIED:20260715T180733Z
UID:8368-1552003200-1552175999@www.ede.gr
SUMMARY:European NASH Workshop 2019 (8 - 9/3/2019\, Βαρκελώνη)
DESCRIPTION:We are proud to announce the first edition of the European NASH Workshop 2019. The workshop is scheduled for March 8-9 2019 and will take place in Barcelona\, Spain. \n\nBACKGROUND\nNon-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of the population worldwide. In 10% of patients\, NAFLD progresses into NASH\, a fibrogenic phenotype that can potentially result in cirrhosis\, liver failure and the formation of hepatocellular carcinoma.\nAlthough NAFLD is globally the most prevalent chronic liver disease and the second leading indication for liver transplant evaluation in the US\, knowledge concerning the molecular mechanisms favoring the development and progression of the disease are not fully understood. Current understanding supports the hypothesis that environmental and genetic factors equally influence disease progression.\nConsidering the far-reaching societal and economic burden caused by NAFLD\, it is of utmost importance to identify and subsequently implement guidelines to stage\, diagnose and treat the disease efficiently.\nIn particular\, there is an unmet need for approved drugs that allow the pharmacological treatment of (pre-)cirrhotic NASH. By using surrogate endpoints\, the drug approval process for NASH is accelerated and approved agents are expected to enter the market in the near future. \nThis workshop aims to train clincians on current and future treatment options. We specifically aim to provide practical guidance to secondary stakeholders\, such as endocrinologists\, diabetologists\, cardiologists and general practitioners\, on how to manage NAFLD/NASH. \n  \n 
URL:https://www.ede.gr/event/european-nash-workshop-2019-8-9-3-2019-varkeloni/
CATEGORIES:Παγκόσμια Συνέδρια
ATTACH;FMTTYPE=image/jpeg:https://www.ede.gr/wp-content/uploads/2025/01/Logo_EUNASH-2.jpg
END:VEVENT
END:VCALENDAR